1. Health Canada. Summary Safety Review - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the risk of the body producing high levels of acids in the blood (diabetic ketoacidosis). Available from URL:
https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin.html
(accessed August 2017).
2. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015; 75: 33-59.
3. Anonymous. Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes 2016; 40: 193-5.
4. U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from URL: https://www.fda.gov/downloads/drugs/drugsafety/ucm446954.pdf (accessed August 2017).
5. Tang H, Li D, Wang T, Zhai S, Song Y. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2016; 39: e123-4.